drugset / Trial / NCT04392960

Novel Imaging Tools in Newly-diagnosed Patients With Cardiac AL Amyloidosis

NCT04392960

NaSingle-groupOpen-labelDiagnostic

Summary

This will be a systematic, combined, prospective assessment of the novel echographic, CMR, and PET imaging tools in newly-diagnosed patients with cardiac AL amyloidosis at baseline and after treatment.

Timeline

Start
2020-07-22
Primary completion
2025-06-30
Completion
2025-06-30

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject 18F-Florbetaben Diagnostic / imaging agent 370 mbq Intravenous

Indications